{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-23-002985","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2023-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.492604+00:00","generated_at":"2026-06-10T01:39:19.412451+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Relmada reports positive preclinical psilocybin data for MASLD; Phase 1 in early 2024","bullets":["Low-dose psilocybin (0.05 mg/kg, daily oral) in HFHFD mice reduced liver steatosis, body weight (12% reduction), and fasting blood glucose (p<0.05).","Mechanism involves 5-HT-2A receptor agonism, distinct from GLP-1 agents; restored plasma/liver triglyceride levels to normal-diet levels.","Company to initiate single-ascending dose Phase 1 trial in obese MASLD patients in early 2024.","Data to be presented at AASLD The Liver Meeting 2023 (Nov 10-14, 2023, Boston)."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-23-002985","json":"https://secwatch.observer/filing/0001013762-23-002985.json","markdown":"https://secwatch.observer/filing/0001013762-23-002985.md","text":"https://secwatch.observer/filing/0001013762-23-002985.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000101376223002985/0001013762-23-002985-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000101376223002985/ea186600-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T01:39:19.412451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}